Table 2.

FDG-PET assessment of tumor response to standard therapy in multiple cancer types and correlation with patient outcome

Tumor/treatment (n)nCriteriaEnd point (P)FDG-PET responderFDG-PET nonresponderReference
    CRT (13) or chemotherapy (41)54Visual1-y OS (<0.0001)92%50%(190)
1-y PFS (<0.0001)86%0%
    Anthracycline-, mitoxantrone-, or cisplatin-based chemotherapy28VisualOS (<0.0001): 1 y87%20%(182)
2 y68%0%
PFS (<0.0001): 1 y81%20%
2 y62%0%
    Doxorubicin-based or CVP93VisualPFS (<0.00001): median653 d73 d(180)
2 y85%4%
    High-dose chemotherapy (Hodgkin's disease: MOPP/ABV or Stanford V regimen (269); non–Hodgkin's lymphoma: CHOP or CHVmP/BV) + SCT60Visual2-y OS (<0.00002)100%55%(181)
PFS (<0.000001): median1,466 d432 d
2 y96%23%
    Induction treatment + high-dose chemotherapy with (9) or without radiotherapy (15) + SCT22SUV (↓25%)Median OS (0.006)>60 mo14 mo(183)
Median PFS (0.006)25 mo4 mo
    Chemotherapy, radiotherapy, or CRT with (2) or without (54) SCT56VisualPFS (<0.0025)21 mo2 mo(184)
SUV (below mean)PFS (<0.05)≥10 mo4 mo
    Chemotherapy (11), radiotherapy (1), CRT (8), or salvage chemotherapy with (6) or without (2) SCT28VisualDFS (0.004)95%40%(270)
    Chemotherapy (20), CRT (34), and/or SCT (7)58SUV (<3) in residual massPFS (<0.00001)>48 mo18 mo(185)
Recurrence rate (0.004)4%62.5%
CHOP, DEXA-ICE, or DBVD30Visual, after first cyclePFS (<0.001)>25 mo5 mo(188)
    High-dose chemotherapy + SCT16Visual1-y OS (0.01)100%55%(271)
1-y relapse-free survival (0.01)100%18%
    DHAP-VIM ± SCT46Visual2-y PFS (0.048)62%32%(272)
    Cyclophosphamide, doxorubicin, premarin, methotrexate, 5-FU, tamoxifen, radiotherapy11SUV (↓48%)6-mo DFS (<0.0001)73%27%(214)
    Gemcitabine, epirubicin, and paclitaxel or epirubicin and paclitaxel9SUVPFS (significant)∼15 mo∼5 mo(218)
    Neoadjuvant therapy (doxorubicin or cyclophosphamide ± 5-FU; cyclophosphamide + methotrexate + 5-FU + radiotherapy; paclitaxel or docetaxel + vinrelobine; or paclitaxel + Herceptin)31FDG metabolic rateDFS (0.09-0.05)>60 mo∼35 mo(273)
    5-FU (10) or tegafur (15) ± radiotherapy25SUV (<6)3 y (0.04)92%60%(225)
    Neoadjuvant 5-FU/leucovorin and radiotherapy15SUV (↓62%)OS (0.08)>50 mo40 mo(226)
DFS (0.02)>50 mo∼25 mo
    Neoadjuvant 5-FU and radiotherapy24SUV (↓52%)OS (<0.0001)22.5 mo8.8 mo(169)
    Neoadjuvant 5-FU, cisplatin and radiotherapy36VisualOS (0.002)16.3 mo6.4 mo(170)
    Neoadjuvant paclitaxel, cisplatin ± radiotherapy39SUV (↓60%)2-y OS (0.089)67%38%(171)
2-y DFS (0.055)89%63%
    Neoadjuvant 5-FU, leucovorin and cisplatin ± paclitaxel40SUV (↓35%)OS (0.04): 2 y60%37%(168)
Median>53 mo13 mo
PFS (0.01)>53 mo10 mo
    Neoadjuvant 5-FU, radiotherapy38SUV (↓30%)OS (0.011)>38 mo18 mo(172)
    CRT63VisualOS (0.012)22 mo<15 mo(69)
    Radiotherapy (10) or CRT [carboplatin (47) or cisplatin + either taxol (6), 5-FU (9), or VP-16 (1)]73VisualOS (<0.0001)36 mo12 mo(163)
    Vinorelbine, etoposide or docetaxel + cisplatin, or paclitaxel and carboplatin57SUV (↓20%)OS (0.005): median252 d151 d(161)
1 y44%10%
PFS (0.003)163 d54 d
    Neoadjuvant radiotherapy and cisplatin35SUV<43-y OS (0.046)80%43%(274)
    Neoadjuvant radiotherapy (37) or CRT (10)47FDG metabolic rate (below median)5-y OS (0.0042)72%35%178)
    Radiotherapy alone (20) or with cisplatin (132)152Visual5-y OS (<0.001)92%46% (0% if new FDG uptake sites)(143)
    Radiotherapy with cisplatin47VisualOS (<0.0005)73%0%(223)
    Imatinib mesylate21SUV [EORTC (212)]1-y PFS (0.00107)92%12%(208)
  • Abbreviations: CRT, chemoradiotherapy; SCT, stem cell transplant; CVP, cyclophosphamide, vincristine, prednisone; MOPP/ABV, mechlorethamine, Oncovin (vincristine sulfate), procarbazine, prednisone, Adriamycin (doxorubicin), bleomycin, vinblastine; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CHVmP/BV, cyclophosphamide, doxorubicin, teniposide, prednisone, bleomycin, vincristine; Induction treatment, Anthracycline-, mitoxantrone-based chemotherapy, B-ALL protocol, or DEXA-BEAM; high dose chemotherapy, endoxan or cyclophasphamide, etoposide, and carmustine; DEXA-ICE, dexamethasone, ifosfamide, cisplatin, and etoposide; DBVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; DHAP-VIM, dexamethasone, cytarabine, and cisplatin followed by etoposide, iphosphamide, and methotrexate; EORTC, European Organization for Research and Treatment of Cancer criteria.